Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04971434
Other study ID # P.T.REC/012/003251
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 11, 2021
Est. completion date December 1, 2021

Study information

Verified date July 2021
Source Cairo University
Contact Ali Ismail, lecturer
Phone 02 01005154209
Email allooka2012@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Every-two-week applied cupping (with scarification) session within one month on back of upper thorax is not compared previously regarding its effect on cardio-metabolic risk factors to the daily application of laser on acupoints (for month, except Fridays) in fatty liver patients. This trial will compare the two procedure effects on cardio-metabolic risk factors in fatty liver.


Description:

In fatty liver patients,every-two-week applied cupping (with scarification) session within one month on back of upper thorax for 30 patients will be compared regarding its effect on cardio-metabolic risk factors to the daily application of laser on acupoints (for month, except Fridays) of other 30 patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 1, 2021
Est. primary completion date December 1, 2021
Accepts healthy volunteers No
Gender All
Age group 35 Years to 55 Years
Eligibility Inclusion Criteria: - Diagnosed Fatty liver patients by ultrasonography - Class I obese patients Exclusion Criteria: - Cardiovascular and respiratory disorders/diseases. - Autoimmune disorders/diseases. - Pregnancy - Other liver disorders/diseases.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
laser stimulation for acupoints
In fatty liver patients (30 patients), a daily application of 4-minute laser (for one month, except Fridays) on acupoint number 25,40,36 of stomach meridian, acupoint number 3 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9,12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
Other:
cupping with scarification
In fatty liver patients (30 patients),every-two-week applied cupping (with scarification) session within one month on back of upper thorax

Locations

Country Name City State
Egypt Faculty of Physical Therapy Cairo University Giza Dokki

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary high-density lipoprotein serum lipid It will be measured after 4 weeks of treatment
Primary low-density lipoprotein serum lipid It will be measured after 4 weeks of treatment
Primary cholesterol serum lipid It will be measured after 4 weeks of treatment
Primary triglyceride serum lipid It will be measured after 4 weeks of treatment
Secondary c reactive protein it will be measured in plasma It will be measured after 4 weeks of treatment
Secondary blood glucose fasting gluocse It will be measured after 4 weeks of treatment
Secondary blood pressure it will be measure with manual manometer It will be measured after 4 weeks of treatment
Secondary rate of pulse it will be measured at radial artery It will be measured after 4 weeks of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis Phase 2
Recruiting NCT06051669 - Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
Not yet recruiting NCT05984745 - Effect of CoQ10 on the Outcome of MAFLD Patients Phase 2
Completed NCT02565446 - Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram N/A
Not yet recruiting NCT01694342 - Telomere Parameters in Patients With Nonalcoholic Fatty Liver N/A
Completed NCT01464801 - Resveratrol in Patients With Non-alcoholic Fatty Liver Disease N/A
Completed NCT01992809 - Omega 3 Supplementation in Fatty Liver Phase 3
Completed NCT00244569 - Development of a Breath Test for Monitoring Patients With Liver Disease Phase 3
Completed NCT00063635 - Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) Phase 3
Recruiting NCT03972319 - Omega-3 Supplementation for LIver VolumE Reduction Study (OLIVER) Study Early Phase 1
Completed NCT03141008 - Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet
Completed NCT03614039 - Effect of Probiotic and Smectite Gel on NAFLD N/A
Recruiting NCT05125757 - Lifestyle Modification in Psoriatic Patients With Fatty Liver N/A
Recruiting NCT05370053 - The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology N/A
Recruiting NCT04371042 - PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
Completed NCT04004273 - Diabetes, Exercise and Liver Fat (DELIVER) N/A
Completed NCT02520609 - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Recruiting NCT02265276 - A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease Phase 3
Completed NCT02347007 - Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults N/A
Completed NCT01934777 - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Phase 3